These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 15003712)

  • 1. Increased serum concentration of nerve growth factor in patients with microprolactinoma.
    Sigala S; Martocchia A; Missale C; Falaschi P; Spano P
    Neuropeptides; 2004 Feb; 38(1):21-4. PubMed ID: 15003712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
    Bevan JS; Burke CW
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRL as a novel potent cofactor for platelet aggregation.
    Wallaschofski H; Donné M; Eigenthaler M; Hentschel B; Faber R; Stepan H; Koksch M; Lohmann T
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5912-9. PubMed ID: 11739463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
    Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of prolactin-releasing response to salsolinol (SAL) and thyrotropin-releasing hormone (TRH) in ruminants.
    Hashizume T; Onodera Y; Shida R; Isobe E; Suzuki S; Sawai K; Kasuya E; Nagy GM
    Domest Anim Endocrinol; 2009 Feb; 36(2):99-104. PubMed ID: 19070987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between salsolinol (SAL) and thyrotropin-releasing hormone (TRH) or dopamine (DA) on the secretion of prolactin in ruminants.
    Hashizume T; Shida R; Suzuki S; Kasuya E; Kuwayama H; Suzuki H; Oláh M; Nagy GM
    Domest Anim Endocrinol; 2008 Apr; 34(3):327-32. PubMed ID: 17976947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteocalcin levels in patients with microprolactinoma before and during medical treatment.
    Sartorio A; Conti A; Ambrosi B; Muratori M; Morabito F; Faglia G
    J Endocrinol Invest; 1990 May; 13(5):419-22. PubMed ID: 1974270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
    Delgrange E; Duprez T; Maiter D
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
    Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyrotrophin-releasing hormone, vasoactive intestinal peptide, prolactin-releasing peptide and dopamine regulation of prolactin secretion by different lactotroph morphological subtypes in the rat.
    Christian HC; Chapman LP; Morris JF
    J Neuroendocrinol; 2007 Aug; 19(8):605-13. PubMed ID: 17620102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential involvement of protein kinase C in basal versus acetylcholine-regulated prolactin secretion in rat anterior pituitary cells during aging.
    Pu HF; Liu TC
    J Cell Biochem; 2002; 86(2):268-76. PubMed ID: 12111996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
    Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
    Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of endocrine tests. A: the TRH test in patients with hyperprolactinaemia.
    Le Moli R; Endert E; Fliers E; Prummel MF; Wiersinga WM
    Neth J Med; 2003 Feb; 61(2):44-8. PubMed ID: 12735420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of macroprolactinoma and elevated insulin-like growth factor-I in a young boy.
    Eyal O; Naffaa LN; Elder DA
    Acta Paediatr; 2005 Dec; 94(12):1852-4. PubMed ID: 16421054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.